

# Miroslav Odinak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5896177/publications.pdf>

Version: 2024-02-01

23  
papers

1,095  
citations

1307594

7  
h-index

752698

20  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1640  
citing authors

#	ARTICLE	IF	CITATIONS
1	The algorithm of reperfusion treatment of the ischemic stroke: focus on DAWN and DEFUSE-3 trials. Arterial Hypertension (Russian Federation), 2021, 27, 29-40.	0.4	1
2	Signs and Symptoms of Central Nervous System Involvement and Their Pathogenesis in COVID-19 According to The Clinical Data (Review). Obshchaya Reanimatologiya, 2021, 17, 65-77.	1.0	1
3	Thalamic nuclei degeneration in multiple sclerosis. Journal of Clinical Neuroscience, 2021, 89, 375-380.	1.5	6
4	Mozart effect in patients with epilepsy. Epilepsy and Paroxysmal Conditions, 2021, 13, 264-273.	0.5	0
5	Changes in retinal structures as markers of multiple sclerosis progression. Neurologiya, Neiropsikhiatriya, Psikhosomatika, 2021, 13, 55-61.	1.2	1
6	The Effect of Iron Accumulation in the Basal Ganglia on the Dysfunction of the Extrapyramidal System in Parkinson's Disease. Russian Neurological Journal, 2020, 25, 29-37.	0.3	1
7	Susceptibility-weighted MR imaging (SWI) of basal ganglia iron deposition in the early and advanced stages of Parkinson's disease. Neurologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 30-36.	1.2	4
8	A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Glatiramer Acetate 20 mg in Patients with Remitting Multiple Sclerosis: First-Year Study Results. Neuroscience and Behavioral Physiology, 2018, 48, 351-357.	0.4	6
9	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
10	Cortical cerebral atrophy in patients with Parkinson's disease: New opportunities for in vivo diagnostics. Human Physiology, 2016, 42, 905-909.	0.4	0
11	Opportunities in multimodal neuroimaging for optimizing thrombolytic therapy for ischemic stroke. Neurologiya, Neiropsikhiatriya, Psikhosomatika, 2016, 8, 9-15.	1.2	4
12	A.A. Mikhailenko, M.M. Odina, N.N. Yakhno «The history of Russian neurology, The Moscow neurological school». St. Petersburg. 2015;511. Zhurnal Nevrologii i Psikhatrii Imeni S S Korsakova, 2016, 116, 130.	0.7	0
13	Use of Succinates for Correction of Metabolic Impairments in the Ischemic Penumbra Zone in Stroke Patients. Neuroscience and Behavioral Physiology, 2015, 45, 600-604.	0.4	0
14	Correction of Subdementia Cognitive Impairments in Patients with Cerebral Ischemia. Neuroscience and Behavioral Physiology, 2014, 44, 927-932.	0.4	0
15	Transplantation of Mesenchymal Stem Cells in Multiple Sclerosis. Neuroscience and Behavioral Physiology, 2012, 42, 516-520.	0.4	4
16	Treatment of Exacerbations of Multiple Sclerosis without the Use of Corticosteroids: The Role of Metabolic and Antioxidant Therapy. Neuroscience and Behavioral Physiology, 2012, 42, 123-127.	0.4	9
17	Potential of Preventive Treatment of Alzheimer's Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome. Neuroscience and Behavioral Physiology, 2011, 41, 391-398.	0.4	2
18	Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson's Disease Complicated by Dementia. Neuroscience and Behavioral Physiology, 2010, 40, 149-155.	0.4	47

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open) Tj ETQq1	1,0784314 0,4	119
20	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 611-620.	5.3	171
21	The Ergotropic Activity Index as an Integral Indicator of the Suprasegmental Autonomic Activity. <i>Human Physiology</i> , 2003, 29, 318-323.	0.4	0
22	Perfluorodecalin-induced changes in clinical and immunological parameters of experimental allergic encephalomyelitis. <i>Bulletin of Experimental Biology and Medicine</i> , 1997, 123, 273-275.	0.8	0
23	Clinical-Morphological Risk Factors for the Development of Epilepsy in Patients with Glial and Metastatic Brain Tumors. <i>Neuroscience and Behavioral Physiology</i> , 0, , .	0.4	0